Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE: EBS), currently trading at $6.31 with a market capitalization of $342.5 million, will be added to the Russell 3000 Index effective after U.S. markets close on June 27, 2025, as part of the annual reconstitution of Russell U.S. stock indexes.
Joe Papa, president and chief executive officer of Emergent BioSolutions, called the inclusion "an important milestone in Emergent’s ongoing transformation."
The Russell 3000 Index captures the 4,000 largest U.S. stocks as of April 30, 2025, ranked by total market capitalization. Membership in the index, which remains in place for one year, includes automatic inclusion in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index.
FTSE Russell determines membership for its Russell indexes primarily through objective market-capitalization rankings and style attributes. According to data from December 2023, approximately $10.5 trillion in assets are benchmarked against Russell U.S. indexes.
Emergent BioSolutions develops and delivers protective solutions for health threats including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.
The announcement was made in a press release statement from the company.
In other recent news, Emergent BioSolutions reported a notable 656% increase in net income for the first quarter of 2025, reaching $68 million. Despite a decrease in total revenues to $222 million compared to the previous year, the company showed significant improvements in profitability, with an adjusted EBITDA margin of 35%, which is a 1,300 basis point improvement. Emergent BioSolutions has also reaffirmed its full-year revenue guidance for 2025, projecting revenues between $750 million and $850 million, with adjusted EBITDA expected to range from $150 million to $200 million. The company has been focusing on strategic divestitures and restructuring efforts, which have successfully reduced operating expenses by 32%.
Additionally, Emergent BioSolutions continues to lead in the naloxone market with its NARCAN nasal spray, which remains a key component of its product portfolio. The company recently secured a three-year agreement with the province of Ontario valued at approximately $65 million for the supply of NARCAN. Emergent BioSolutions is also expanding its international reach, with 40% of its first-quarter revenue coming from outside the United States, highlighting its global growth strategy. Furthermore, the company is actively managing its cash position, with $149 million in cash and a total liquidity of $249 million, enabling it to pursue strategic growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.